Company: IMNN
Filing Date: 2025-05-19
Form Type: S-1/A
Source: 0001641172-25-011388
Chunk: 2

Company: Imunon, Inc.
Filing Date: 2025-05-19
Form: S-1/A
Chunk 2
---
 COMMON WARRANTS TO PURCHASE 73,333,333 SHARES OF COMMON STOCK*

UP TO 16,666,667 PRE-FUNDED WARRANTS TO PURCHASE 16,666,667 SHARES OF COMMON STOCK

UP TO 73,333,333 SHARES OF COMMON STOCK UNDERLYING SUCH COMMON WARRANTS*

UP TO 16,666,667 SHARES OF COMMON STOCK UNDERLYING SUCH PRE-FUNDED WARRANTS</div>

We are offering on a reasonable best-efforts basis up to 16,666,667 shares of our common stock, par value $0.01 per share (“ Common Stock”), together with warrants to purchase up to 73,333,333 shares of our Common Stock based on an assumed public offering price of $0.48 per share of Common Stock and accompanying warrant, which was the closing price of our Common Stock on the Nasdaq Stock Market (“ Nasdaq”) on May 16, 2025. Each share of Common Stock, or a pre-funded warrant in lieu thereof, is being sold together with a common warrant to purchase one share of Common Stock. The shares of Common Stock, or pre-funded warrants in lieu thereof, and common warrants are immediately separable and will be issued separately in this offering but must be purchased together in this offering. This prospectus also relates to the shares of Common Stock issuable upon exercise of the pre-funded warrants and the common warrants sold in this offering.

The common warrants will be exercisable upon receipt of stockholder approval, including such approval as may be required by the applicable rules and regulations of Nasdaq from the stockholders of the Company and board of directors of the Company: (a) to consent to any adjustment to the exercise price and/or number of shares of Common Stock underlying the common warrants in the event of an adjustment upon the Adjustment Date (as defined below) pursuant to the terms of the common warrants, (b) to consent to any adjustment to the exercise price of the common warrants in the event of a voluntary adjustment pursuant to the terms of the common warrants, and (c) to consent to the “zero exercise price” provision of the common warrants (referred to in the text of the common warrants as an “alternative cashless exercise”) (collectively, the “ Stockholder Approval”). “Adjustment Date” means the close of trading on the 11th trading day after the trading day on which we file a Current Report on Form 8-K with the Securities and Exchange Commission (the “SEC”) giving public notice of Stock